Identification

Name
Tegafur
Accession Number
DB09256
Type
Small Molecule
Groups
Approved, Investigational
Description

Tegafur (INN, BAN, USAN) is a prodrug of Fluorouracil (5-FU), an antineoplastic agent used as the treatment of various cancers such as advanced gastric and colorectal cancers. It is a pyrimidine analogue used in combination therapies as an active chemotherapeutic agent in conjunction with Gimeracil and Oteracil, or along with Fluorouracil as Tegafur-uracil. Tegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by ensuring high concentrations of 5-FU at a lower dose of tegafur [5]. When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the World Health Organization's List of Essential Medicines.

Structure
Thumb
Synonyms
  • 1-(2-Tetrahydrofuryl)-5-fluorouracil
External IDs
MJF-12264
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
TeysunoTegafur (20 mg) + Gimeracil (5.8 mg) + Oteracil (15.8 mg)CapsuleOralNordic Group Bv2011-03-14Not applicableEu
TeysunoTegafur (15 mg) + Gimeracil (4.35 mg) + Oteracil (11.8 mg)CapsuleOralNordic Group Bv2011-03-14Not applicableEu
TeysunoTegafur (20 mg) + Gimeracil (5.8 mg) + Oteracil (15.8 mg)CapsuleOralNordic Group Bv2011-03-14Not applicableEu
TeysunoTegafur (15 mg) + Gimeracil (4.35 mg) + Oteracil (11.8 mg)CapsuleOralNordic Group Bv2011-03-14Not applicableEu
TeysunoTegafur (15 mg) + Gimeracil (4.35 mg) + Oteracil (11.8 mg)CapsuleOralNordic Group Bv2011-03-14Not applicableEu
International/Other Brands
Ai Yi (Hengrui) / ESUEEW AN T (Sawai Seiyaku) / Fimer (LKM) / Ftorafur (Grindeks) / Furil (Lotus Pharmaceuticals) / Futraful (Taiho) / Icarus (Koa Isei) / Lunacin (Sawai Seiyaku) / NKS-1 T (Nippon Kayaku) / Qi Xing (Hualu Pharmaceutical) / S-1 (Taiho) / Sterozine (Kotobuki Seiyaku) / Tefudex (Korea United Pharma) / Tegacin (Patron) / Tegracil (Shin Poong) / Teroful (Kwang Dong) / TS-1 (Toho Yakuhin) / TS-ONE (Taiho) / UFT (Merck) / Ufur (TTY) / Unitoral (Korea United Pharm) / Utefos (Mylan)
Categories
UNII
1548R74NSZ
CAS number
17902-23-7
Weight
Average: 200.169
Monoisotopic: 200.059720321
Chemical Formula
C8H9FN2O3
InChI Key
WFWLQNSHRPWKFK-UHFFFAOYSA-N
InChI
InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)
IUPAC Name
5-fluoro-1-(oxolan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
FC1=CN(C2CCCO2)C(=O)NC1=O

Pharmacology

Indication

Indicated for the treatment of cancer usually in combination with other biochemically modulating drugs.

Indicated in adults for the treatment of advanced gastric cancer when given in combination with Cisplatin [5].

Indicated for the first-line treatment of metastatic colorectal cancer with Uracil and calcium folinate [6].

Associated Conditions
Pharmacodynamics

Tegafur is an antineoplastic agent that belongs in the class of pyrimidine analogues. It interferes with the 2'-deoxythymidylate (DTMP) synthesis in the pyrimidine pathway, resulting in inhibition of DNA synthesis [4]. In a phase III trial investigating the clinical efficacy of S-1 (tegafur/gimeracil/oteracil) in patients with advanced or recurrent gastric cancer, treatment resulted in a high response rate and was associated with a longer overall survival and longer progression-free survival rate when used in combination with cisplatin [1]. In a meta analysis, triple combination therapy consisting of tegafur, gimeracil and oteracil showed longer survival times and well tolerance in patients with advanced gastric cancer [2]. Tegafur and its active metabolites are potent myleosuppressive agents [5].

Mechanism of action

The transformation of 2'-deoxyurindylate (dUMP) to 2'-deoxythymidylate (dTMP) is essential in driving the synthesis of DNA and purines in cells [4]. Thymidylate synthase catalyzes the conversion of dUMP to dTMP, which is a precursor of thymidine triphosphate (TTP), one of the four deoxyribonucleotides required for DNA synthesis [3]. After administration into the body, tegafur is converted into the active antineoplastic metabolite, fluorouracil (5-FU). In tumour cells, 5-FU undergoes phosphorylation to form the active anabolites, including 5-fluorodeoxyuridine monophosphate (FdUMP) [5]. FdUMP and reduced folate are bound to thymidylate synthase leading to formation of a ternary complex which inhibits DNA synthesis [5]. In addition, 5-fluorouridine-triphosphate (FUTP) is incorporated into RNA causing disruption of RNA functions [5].

TargetActionsOrganism
AThymidylate synthase
inhibitor
Human
Absorption

Tegafur displays a dose-proportional pharmacokinetic properties. Tegafur is rapidly and well absorbed into the systemic circulation, reaching the peak plasma concentration within 1 to 2 hours of administration [6].

Volume of distribution

The volume of distribution based on apparent volume of distribution and urinary excretion data of tegafur is 16 L/m^2 [5].

Protein binding

Tegafur is 52.3% bound to serum proteins and 5-FU is 18.4% protein bound [5, 6].

Metabolism

Hepatic CYP2A6 is the predominant enzyme that mediates 5-hydroxylation of tegafur to generate 5'-hydroxytegafur. This metabolite is unstable and undergoes spontaneous degradation to form 5-FU, which is an active antineoplastic agent that exerts a pharmacological action on tumours. 5-FU is rapidly metabolised by the liver enzyme dihydropyrimidine dehydrogenase (DPD) [3].

Route of elimination

Following oral administration, about less 20% of total tegafur is excreted unchanged in the urine [6].

Half life

The elimination half life of tegafur is approximately 11 hours [6].

Clearance

No pharmacokinetic data available.

Toxicity

Oral LD50 value in rat, mouse and dog are 930mg/kg, 775mg/kg, and 34mg/kg, respectively [MSDS]. Continuous exposure to tegafur may cause physical defects in the developing embryo (teratogenesis).

Acute toxicity from the combination use of tegafur was associated with nausea, vomiting, diarrhoea, mucositis, gastrointestinal irritation, bleeding, bone marrow depression, and respiratory failure [5]. Overdose may lead to fatal complications [6]. In case of overdose, appropriate therapeutic and supportive medical interventions should be implemented.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*2A(A;A) / (A;G)G > AADR Directly StudiedThe presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from tegafur therapy.Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*13(C;C) / (A;C)A > CADR Directly StudiedThe presence of this genotype in DPYD is associated with an increased risk of drug-related toxicity from tegafur therapy.Details
Dihydropyrimidine dehydrogenase [NADP(+)]---(A;A) / (A;T)T > AADR Directly StudiedThe presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from tegafur therapy.Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*4(G;G) / (A:G)G > AADR Directly StudiedThe presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from tegafur therapy.Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*5(G;G) / (A;G)A > GADR Directly StudiedThe presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from tegafur therapy.Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*6(A;A) / (A;G)G > AADR Directly StudiedThe presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from tegafur therapy.Details
Dihydropyrimidine dehydrogenase [NADP(+)]DPYD*9A(C;C) / (C;T)T > CADR Directly StudiedThe presence of this genotype in DPYD may be associated with an increased risk of drug-related toxicity from tegafur therapy.Details

Interactions

Drug Interactions
DrugInteraction
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Tegafur.
AcetaminophenAcetaminophen may decrease the excretion rate of Tegafur which could result in a higher serum level.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Tegafur.
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Tegafur.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Tegafur which could result in a higher serum level.
AllopurinolThe therapeutic efficacy of Tegafur can be decreased when used in combination with Allopurinol.
AlprazolamAlprazolam may decrease the excretion rate of Tegafur which could result in a higher serum level.
AmilorideAmiloride may increase the excretion rate of Tegafur which could result in a lower serum level and potentially a reduction in efficacy.
AmiodaroneThe serum concentration of the active metabolites of Tegafur can be reduced when Tegafur is used in combination with Amiodarone resulting in a loss in efficacy.
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Tegafur.
Food Interactions
Not Available

References

General References
  1. Tsuburaya A, Morita S, Kodera Y, Kobayashi M, Shitara K, Yamaguchi K, Yoshikawa T, Yoshida K, Yoshino S, Sakamoto J: A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). BMC Cancer. 2012 Jul 23;12:307. doi: 10.1186/1471-2407-12-307. [PubMed:22824079]
  2. Yang J, Zhou Y, Min K, Yao Q, Xu CN: S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: a meta-analysis. World J Gastroenterol. 2014 Sep 7;20(33):11886-93. doi: 10.3748/wjg.v20.i33.11886. [PubMed:25206296]
  3. Kohne CH, Peters GJ: UFT: mechanism of drug action. Oncology (Williston Park). 2000 Oct;14(10 Suppl 9):13-8. [PubMed:11098484]
  4. 55. (2012). In Rang and Dale's Pharmacology (7th ed., pp. 680-681). Edinburgh: Elsevier/Churchill Livingstone. [ISBN:978-0-7020-3471-8]
  5. European Medicines Agency (EMA): TEYSUNO (tegafur/gimeracil/oteracil) Summary of Product Characteristics [Link]
  6. UFT (uracil/tegafur) capsules_Product information [Link]
External Links
KEGG Drug
D01244
KEGG Compound
C12673
PubChem Compound
5386
PubChem Substance
310265158
ChemSpider
5193
ChEBI
32188
ChEMBL
CHEMBL20883
Wikipedia
Tegafur
ATC Codes
L01BC53 — Tegafur, combinationsL01BC03 — Tegafur
MSDS
Download (242 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentEsophageal Cancers1
1CompletedTreatmentMalignant Neoplasm of Stomach / Neoplasms, Gastrointestinal1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentStomach Neoplasms2
1CompletedTreatmentTumors1
1Not Yet RecruitingTreatmentMetastatic Colorectal Cancers1
1RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma1
1RecruitingTreatmentAdvanced Solid Tumors1
1RecruitingTreatmentBiliary Cancers / Gastric Cancer in Situ / Malignant Neoplasm of Pancreas1
1RecruitingTreatmentDigestive Cancers1
1RecruitingTreatmentEsophageal Cancers1
1RecruitingTreatmentHepatocellular,Carcinoma2
1, 2CompletedTreatmentMalignant Neoplasm of Stomach3
1, 2Not Yet RecruitingTreatmentHead and Neck Carcinoma1
1, 2RecruitingTreatmentAdenocarcinoma,Stomach / Esophagogastric Junction Adenocarcinoma1
1, 2SuspendedTreatmentMalignant Neoplasm of Pancreas1
1, 2Unknown StatusTreatmentRectal Carcinoma1
2Active Not RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Metastatic Gastric Adenocarcinoma1
2Active Not RecruitingTreatmentAdvanced Pancreatic Cancer1
2Active Not RecruitingTreatmentBiliary Tract Neoplasms1
2Active Not RecruitingTreatmentMalignant Neoplasm of Pancreas1
2Active Not RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2CompletedDiagnosticMalignant Neoplasm of Stomach1
2CompletedTreatmentAdvanced Non-Small Cell Lung Cancer2
2CompletedTreatmentHepatocellular,Carcinoma2
2CompletedTreatmentLocally Advanced or Metastatic Pancreatic Cancer1
2CompletedTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
2CompletedTreatmentMalignant Neoplasm of Stomach6
2CompletedTreatmentMetastatic Colorectal Cancers2
2CompletedTreatmentSecondary Malignant Neoplasm of Pancreas1
2CompletedTreatmentStomach Neoplasms2
2Enrolling by InvitationTreatmentLocally Advanced or Metastatic Pancreatic Cancer1
2Not Yet RecruitingTreatmentHepatocellular,Carcinoma1
2Not Yet RecruitingTreatmentMalignant Neoplasm of Stomach2
2Not Yet RecruitingTreatmentPancreatic Ductal Adenocarcinoma1
2RecruitingTreatmentAdenocarcinoma Of Esophagus / Adenocarcinomas of the Gastroesophageal Junction / Gastric Adenocarcinoma / Metastatic Esophagogastric Adenocarcinoma / Neoplasm, Gastric / Neoplasms, Esophageal / Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction1
2RecruitingTreatmentAdvanced Pancreatic Cancer1
2RecruitingTreatmentAdvanced or Metastatic Non-Small Cell Lung Cancer1
2RecruitingTreatmentBile Duct Neoplasms / Cancer of Unknown Primary Site / Gastrointestinal Cancers / Malignant Neoplasm of Pancreas1
2RecruitingTreatmentBiliary Tract Neoplasms1
2RecruitingTreatmentCarcinoma, Pancreatic1
2RecruitingTreatmentColorectal Cancers1
2RecruitingTreatmentEsophageal Cancers / Radiotherapy / S-11
2RecruitingTreatmentExtrapancreatic Neuroendocrine Tumor1
2RecruitingTreatmentMalignant Neoplasm of Stomach3
2RecruitingTreatmentMetastatic Gastric Cancers1
2RecruitingTreatmentNasopharyngeal Carcinoma2
2RecruitingTreatmentNeoplasms, Head and Neck1
2RecruitingTreatmentPeritoneal Metastasis / Stomach Neoplasms1
2RecruitingTreatmentProgressive Neuroendocrine Tumors of pancreatic origin1
2RecruitingTreatmentRectal Carcinoma1
2RecruitingTreatmentSquamous Cell Carcinoma of Esophagus1
2SuspendedTreatmentMalignant Neoplasm of Stomach1
2TerminatedTreatmentEsophagus Cancer / Malignant Neoplasm of Colon / Malignant Neoplasm of Stomach / Rectum Cancer / Small Bowel Cancer1
2TerminatedTreatmentMalignant Neoplasm of Pancreas1
2Unknown StatusTreatmentChemoradiotherapy, Adjuvant / Radiotherapy, Intensity-Modulated / Stomach Neoplasms1
2Unknown StatusTreatmentEsophageal Cancers / Malignant Neoplasm of Colon / Malignant Neoplasm of Pancreas / Malignant Neoplasm of Stomach1
2Unknown StatusTreatmentMalignant Neoplasm of Pancreas1
2Unknown StatusTreatmentNeoplasms, Esophageal1
2, 3Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
2, 3RecruitingTreatmentChemoradiation / Esophagogastric Junction Cancer / Esophagus Cancer / Radiotherapy; Complications1
2, 3TerminatedTreatmentEsophageal Cancers1
2, 3TerminatedTreatmentMalignant Neoplasm of Stomach1
3Active Not RecruitingTreatmentMalignant Neoplasm of Stomach1
3CompletedTreatmentCancer, Breast2
3CompletedTreatmentColorectal Cancers2
3CompletedTreatmentColorectal Cancers / Metastases1
3CompletedTreatmentMalignant Neoplasm of Stomach2
3Enrolling by InvitationTreatmentMalignant Neoplasm of Stomach1
3Not Yet RecruitingTreatmentAdenocarcinomas of the Gastroesophageal Junction / Neoplasm, Gastric1
3RecruitingTreatmentAdenocarcinomas / Chemoradiation / Gastrooesophageal Cancer / Locally Advanced Cancer / Stomach Neoplasms1
3RecruitingTreatmentChemoradiation / Esophageal Cancers1
3RecruitingTreatmentMalignant Neoplasm of Stomach3
3RecruitingTreatmentMalignant Neoplasm of Stomach / Stomach Neoplasms2
3RecruitingTreatmentNeoplasms, Esophageal1
3TerminatedTreatmentM0 / N0-2 / Rectal Carcinoma / Stage II/III / T3 or T4 (Only Anal Extension) Rectal Cancer1
3TerminatedTreatmentNeoplasms Metastasis / Neoplasms, Pancreatic1
4Not Yet RecruitingTreatmentNeoadjuvant Therapy / Neoplasms, Breast1
4Unknown StatusTreatmentHepatocellular,Carcinoma1
Not AvailableActive Not RecruitingNot AvailableStage IV Gastric Cancer With Metastasis1
Not AvailableActive Not RecruitingTreatmentCholangiocarcinomas1
Not AvailableRecruitingTreatmentMalignant Neoplasm of Pancreas1
Not AvailableUnknown StatusNot AvailableMalignant Neoplasm of Stomach1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
CapsuleOral
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)339.8-343.4MSDS
water solubilityPartly miscibleMSDS
Predicted Properties
PropertyValueSource
Water Solubility14.0 mg/mLALOGPS
logP-0.09ALOGPS
logP0.024ChemAxon
logS-1.2ALOGPS
pKa (Strongest Acidic)8.08ChemAxon
pKa (Strongest Basic)-4.3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area58.64 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity44.5 m3·mol-1ChemAxon
Polarizability17.52 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - EI-BGC-MSsplash10-00di-9010000000-09f17e43065fd7cafc97
GC-MS Spectrum - CI-BGC-MSsplash10-0089-6900000000-0edac06a6aa07cfd4b9f
GC-MS Spectrum - CI-BGC-MSsplash10-0udi-2190000000-6638249408dce3b6c1ee
GC-MS Spectrum - CI-BGC-MSsplash10-014i-0090000000-dc47df1bb362c454d07d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as halopyrimidines. These are aromatic compounds containing a halogen atom linked to a pyrimidine ring. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Halopyrimidines
Alternative Parents
Pyrimidones / Aryl fluorides / Hydropyrimidines / Vinylogous amides / Heteroaromatic compounds / Tetrahydrofurans / Lactams / Ureas / Oxacyclic compounds / Azacyclic compounds
show 6 more
Substituents
Halopyrimidine / Pyrimidone / Aryl fluoride / Aryl halide / Hydropyrimidine / Tetrahydrofuran / Vinylogous amide / Heteroaromatic compound / Urea / Lactam
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
pyrimidines, organohalogen compound (CHEBI:32188)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Thymidylate synthase activity
Specific Function
Contributes to the de novo mitochondrial thymidylate biosynthesis pathway.
Gene Name
TYMS
Uniprot ID
P04818
Uniprot Name
Thymidylate synthase
Molecular Weight
35715.65 Da

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T: Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63. [PubMed:11095583]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T: Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63. [PubMed:11095583]
  2. Backman JT, Filppula AM, Niemi M, Neuvonen PJ: Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev. 2016 Jan;68(1):168-241. doi: 10.1124/pr.115.011411. [PubMed:26721703]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Const...
Gene Name
CYP2A6
Uniprot ID
P11509
Uniprot Name
Cytochrome P450 2A6
Molecular Weight
56501.005 Da
References
  1. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, Chiba K, Kawaguchi Y: Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res. 2000 Nov;6(11):4409-15. [PubMed:11106261]
  2. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T: Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63. [PubMed:11095583]
  3. Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W, Tanabe S, Saigenji K, Nagayama S, Ikeda K, Nishioka Y, Kamataki T: A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics. 2002 Jun;12(4):299-306. [PubMed:12042667]
  4. UFT (uracil/tegafur) capsules_Product information [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T: Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63. [PubMed:11095583]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T: Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63. [PubMed:11095583]

Drug created on October 26, 2015 10:26 / Updated on September 17, 2018 21:02